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Sciences and ChinesAbstract A rapid, speciﬁc and economic UV spectrophotometric method has been developed
using a solvent composed of water:methanol:acetonitrile (9:0.5:0.5) to determine the levoﬂoxacin
content in bulk and pharmaceutical dosage formulations. At a pre-determined lmax of 292 nm, it
was proved linear in the range of 1.0–12.0 mg/mL, and exhibited good correlation coefﬁcient
(R2¼0.9998) and excellent mean recovery (99.00–100.07%). This method was successfully applied
to the determination of levoﬂoxacin content in ﬁve marketed brands from Bangladesh and the
results were in good agreement with the label claims. The method was validated statistically and by
recovery studies for linearity, precision, repeatability, and reproducibility. The obtained results
proved that the method can be employed for the routine analysis of levoﬂoxacin in bulks as well as
in the commercial formulations.
& 2012 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Levoﬂoxacin or L-oﬂoxacin, the bacteriologically active L-isomer
of the racemic ﬂuoroquinolone oﬂoxacin, is a broad-spectrumersity. Production and hosting by E
.004
7690363.
yahoo.com (M. Maleque)
tute of Materia Medica, Chinese
e Pharmaceutical Association.antimicrobial agent. Levoﬂoxacin acts by inhibiting bacterial
DNA gyrase which is required for DNA replication and thus
causes bacterial lysis [1]. The addition of 6-ﬂuoro and 7-piper-
azinyl groups to the molecule greatly increases their antibacterial
activity. They are commonly referred to as the second generation
ﬂuoroquinolone antibacterial agents and are greatly effective
against both gram-negative and gram-positive bacteria that are
resistant to other antibacterials [2–4].
Several HPLC assay methods have been reported for the
determination of oﬂoxacin or its stereoisomers [5–9]. Litera-
ture survey revealed that various analytical methods such as
high performance thin layer chromatography (HPTLC) [10]
and conductometry [11] have been reported for the estimationlsevier B.V. All rights reserved.
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ods were also reported for estimating levoﬂoxacin using
various solvents like 0.1 M hydrochloric acid [12], 100%
methanol [13] or acetonitrile [14].
In this study, efforts were made to develop a simple, easy
and economic UV spectrophotometric method using a diluent
composed of water:methanol:acetonitrile (9:0.5:0.5) for the
determination of levoﬂoxacin in the raw materials as well as in
the marketed dosage formulations. The developed method was
optimized and validated as per the guidelines of International
Conference on Harmonization (ICH) [15] and demonstrated
excellent speciﬁcity, linearity, precision and accuracy for
levoﬂoxacin.2. Materials and methods
2.1. Apparatus
A Shimadzu UV–visible spectrophotometer (UV mini-1700,
Shimadzu Corporation, Kyoto, Japan) was used for all
absorbance measurements with matched quartz cells.
2.2. Materials
All chemicals and reagents were of analytical or HPLC grade.
Levoﬂoxacin in the form of levoﬂoxacin hemihydrate powder
was provided by Incepta Pharmaceuticals Ltd., Bangladesh,
which was used as the reference standard. Pharmaceutical
grade excipients were obtained from Pharmaceutical Technology
Lab. of State University of Bangladesh.
2.3. Determination of wavelength of maximum absorption
A standard stock solution (LS) of levoﬂoxacin (20 mg/mL) was
prepared using diluents and 3 mL of LS was then diluted to
10 mL with the same diluent to obtain 6 mg/mL levoﬂoxacin
reference solution (LR). An UV spectroscopic scanning (190–
400 nm) was carried out with the LR to determine the lmax for
the detection of levoﬂoxacin using diluent as blank.
2.4. Linearity and range
For linearity study, seven solutions at different concentrations
(1, 2, 4, 6, 8, 10 and 12 mg/mL) were prepared using seven
different aliquots of LS, and the obtained data were used for
the linearity calibration plot. Limit of detection (LOD) and
limit of quantiﬁcation (LOQ) for the assay were also calcu-
lated [15].Table 1 Intra-day and inter-day precision determined for three d
Concentration
(mg/mL)
Intra-day precision
Absorbance
measured
(Mean 7 SD)
RSD (%) Average
potency (
4 0.411370.0006 0.140 98.96
6 0.614770.0006 0.094 98.60
8 0.821070.0010 0.122 98.772.5. Intra-day precision (repeatability) and inter-day
precision study (intermediate precision)
Levoﬂoxacin tablets were ﬁnely powdered and the sample
stock solution (LP) of 20 mg/mL was prepared following
the same dilution pattern of LS. Three different aliquots of
LP were then diluted to 10 mL to obtain the concentrations of
4, 6 and 8 mg/mL. This procedure was repeated in the following
days.
2.6. Stability study
Samples prepared for repeatability study were preserved for
24 h at room temperature and analyzed on the following day
to test for short-term stability.
2.7. Accuracy/recovery study
This study was carried out using pre-formulated granules
containing pure levoﬂoxacin hemihydrate and common excipients.
Calculation was done from the label claim and the average weight
of the ﬁnal product. Previously used dilution pattern was followed
for the granules to obtain ﬁve concentrations—80%, 90%, 100%,
110% and 120% of reference solution.
2.8. Speciﬁcity in the presence of excipients
The test for the speciﬁcity was carried out using only excipients.
Spectra for placebo granules, blank, and sample were com-
pared. Secondly the speciﬁcity was determined by subjecting the
sample solution to accelerated degradation by heat (60 1C) for
72 h in order to verify that none of the degradation products
interfered with the quantiﬁcation of the drug.
2.9. Assay of content of levoﬂoxacin in selected marketed brands
Five market brands of levoﬂoxacin tablet from Bangladesh were
randomly selected and analyzed using the newly developed and
validated method. 3 mL of LS was diluted to 10 mL to obtain
6 mg/mL levoﬂoxacin reference standard solution. Sample
solutions of each brand (6 mg/mL) were also prepared and assayed
for content of levoﬂoxacin against the reference standard.
The content of levoﬂoxacin in the marketed brands was deter-
mined using
Content of levofloxacin %ð Þ per tablet¼ As
Ast
 Wst 5 3
100 50 10
 100 50 10
Ws 5 3 W 
P
100
 CFifferent concentrations of levoﬂoxacin (n¼3).
Inter-day precision
%)
Absorbance
measured
(Mean 7 SD)
RSD (%) Average
potency (%)
0.411070.0010 0.240 98.96
0.615370.0006 0.094 98.70
0.821370.0006 0.070 98.81
M. Maleque et al.456where As is the absorbance of generic sample solution, Ast is the
absorbance of levoﬂoxacin reference standard solution, Ws is the
weight of generic sample powder (mg), Wst is the weight of
levoﬂoxacin reference standard powder (mg), W is the average
weight of tablet (mg), P is the potency of standard levoﬂoxacin
hemihydrates and CF is the conversion factor of levoﬂoxacin
hemihydrate to levoﬂoxacin (0.976).Table 2 Short term stability determined by the proposed
method (n¼3).
Conc.
declared (mg/
mL)
Conc. found
(mean7SD, mg/mL)
RSD
(%)
Average
potency
(%)
2 1.96370.006 0.295 98.19
4 3.95770.006 0.146 98.91
6 5.96370.006 0.097 99.41
Table 3 Recovery/accuracy for ﬁve different concentra-
tions of levoﬂoxacin by the proposed method.
Dosage form Label
claim
Amount added
(%)
Recovery
(%)
Pre formulated
granules
500 mg 80 99.05
90 100.07
100 99.43
110 99.00
120 99.66
Figure 1 Speciﬁcity of the method determined by comparing the
spectra of accuracy sample, placebo and degradation products.
Table 4 Content of levoﬂoxacin in ﬁve marketed products deter
Brand Label claim (mg) Amount found (m
Brand 1 500 495.270.7
Brand 2 500 491.470.5
Brand 3 500 492.770.5
Brand 4 250 248.070.2
Brand 5 250 248.770.33. Results and discussion
3.1. Method development and optimization
Levoﬂoxacin is almost insoluble in aqueous medium and freely
soluble in organic solvents like methanol and acetonitrile.
During the development phase, the use of a few milliliters of
acetonitrile and methanol with water as the diluent resulted in
preferable outcome in UV analysis. The solvent composition
was optimized to water (9):methanol (0.5):acetonitrile (0.5).
The pre-determined wavelength of maximum absorption
(lmax) was 292 nm.3.2. Method validation
3.2.1. Linearity and range
The calibration curve obtained was evaluated by its correla-
tion coefﬁcient. The absorbance of the samples in the range of
1.0–12.0 mg/mL was linear with a correlation coefﬁcient (R2)
greater than 0.999. The LOD and LOQ were calculated as
0.021 mg/mL and 0.064 mg/mL respectively.3.2.2. Intra-day and inter-day precision
The intra-day and inter-day precision study (Table 1) of the
developed method conﬁrmed adequate sample stability and
method reliability where all the RSDs were o2%.3.2.3. Stability
Stability study’s results were within the acceptance range
(Table 2) and indicated the samples stability over 24 h
(short-term).3.2.4. Accuracy/recovery
Results within the range of 99.00–100.07% ensure an accurate
method (Table 3) as well as indicate non-interference with the
excipients of formulation.3.2.5. Speciﬁcity in the presence of excipients
The speciﬁcity of the analytical method was proved by
comparing the spectra of placebo and degradation product
of sample solution with that of accuracy sample (Fig. 1).3.2.6. Content of levoﬂoxacin in marketed brands
Levoﬂoxacin content of ﬁve marketed products determined by
the proposed method (Table 4) was in good agreement with
the label claims and was in the range of 98.05–99.47% with the
RSD values of 0.067–0.140% respectively.mined by the proposed method.
ean7SD, mg) Potency (%) RSD (%)
99.05 0.140
98.05 0.094
98.54 0.094
99.19 0.067
99.47 0.128
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The results and the statistical parameters demonstrate that the
proposed UV spectrophotometric method is simple, rapid,
speciﬁc, accurate and precise. Therefore, this method can be
used for the determination of levoﬂoxacin either in bulk or in
the dosage formulations without interference with commonly
used excipients and related substances.
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